Rossella Stella
Trieste, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
High JAK2V617F allele burden in low-risk PV: an additional recommendation to start "early" cytoreduction? Results from a multicentric study.
Journal: Leukemia research
Published: July 24, 2025
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC".
Journal: Cancer medicine
Published: May 28, 2022
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Journal: Cancer
Published: January 18, 2021
Cytomegalovirus Prophylaxis versus Pre-emptive Strategy: Different CD4+ and CD8+ T Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: October 30, 2020
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Journal: Annals of hematology
Published: October 26, 2020
Risk Factors and Outcome of C. difficile Infection after Hematopoietic Stem Cell Transplantation.
Journal: Journal of clinical medicine
Published: October 17, 2020
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Journal: Blood cancer journal
Published: September 25, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Journal: British journal of haematology
Published: July 26, 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Journal: Annals of hematology
Published: April 29, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026